This study is comparing Ramucirumab + Pembrolizumab vs standard of care chemo for patients previously treated with immunotherapy. You must be diagnosed with stage 4 or recurrent Non-Small Cell Lung Cancer (NSCLC).
Contact phoneTracy Bellefeuil | 517.364.2835
Principal investigatorDr. Gordan Srkalovic, MD, PhD
Trial SubCategoryMetastatic Non-Small Cell Lung